TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›BJDX›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Bluejay Diagnostics, Inc. (BJDX) financials

Income statement

Bluejay Diagnostics, Inc. (BJDX) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Revenue——$249K———
Gross profit——$48.9K———
Gross margin——19.6%———
Operating income-$1.20M-$3.23M-$9.32M-$10.3M-$7.17M-$6.95M
Operating margin——-3741.5%———
Net income-$1.16M-$3.49M-$9.30M-$9.95M-$7.72M-$6.85M
Net margin——-3733.1%———
EPS (diluted)-$0.37-$0.41-$9.22-$3,631.48-$456.75-$15.25

Cash flow

Bluejay Diagnostics, Inc. (BJDX) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$509K-$4.37M-$7.74M-$8.31M-$7.82M-$6.05M
Capital expenditures—$23.9K$1.20M$704K$307K$174K
Free cash flow—-$4.39M-$8.94M-$9.02M-$8.13M-$6.23M

Balance sheet

Bluejay Diagnostics, Inc. (BJDX) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$912K$19.0M$10.1M$2.21M$4.30M$5.16M
Total assets$1.52M$21.0M$13.5M$4.87M$6.66M$7.12M
Total liabilities$1.85M$637K$1.98M$1.97M$928K$1.14M
Shareholders' equity-$4.21M$20.4M$11.5M$2.89M$5.73M$5.98M
Retained earnings-$4.21M-$7.69M-$17.0M-$27.0M-$34.7M-$41.5M
Shares (wtd avg diluted)3.15M8.52M1.01M2.74B45.8B449K

Every figure is extracted from Bluejay Diagnostics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Bluejay Diagnostics, Inc.'s free cash flow?
-$6.23M in FY2025 (operating cash flow -$6.05M minus $174K of capital expenditures), from the SEC cash-flow statement.
Does BJDX pay a dividend?
Bluejay Diagnostics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full BJDX analysis — verdict, score & filings →Is BJDX a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.